Miglustat (OGT 918 N-butyl-deoxynojirimycin) is a drug developed by Oxford GlycoSciences and marketed by Actelion and is used primarily to treat Type I Gaucher disease (GD1). It is marketed under the trade name Zavesca. Miglustat is an imino sugar a synthetic analogue of D-glucose and a white to off-white crystalline solid that has a bitter taste.
This page contains content from the copyrighted Wikipedia article "Miglustat"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
